Evaluation of the Effect of Hormone-Free Creams Compare to Estrogenic Creams in Postmenopausal Women with Vulvovaginal Atrophy

Phase 3

Conditions: Postmenopausal atrophic vaginitis.
Postmenopausal atrophic vaginitis
N95.2

Registration Number: IRCT20230408057852N1

Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Female

Target Recruitment: 180

Inclusion Criteria

Postmenopausal women who have been passed at least 1 year since their last period stopped.
The one who have at least one of the vulvovaginal atrophy symptoms such as dryness , burning , itching vulve and vagina and dysparonia
Having satisfaction for using each types of medications which offers randomly

Exclusion Criteria

Having contraindications of Estrogenic medications such as coronary artery disease , thromboemboli , previous thrombophlebitis , malignancies which are sensitive to Estrogenic-Hormone receptors like breast cancer , endometr or ovaries cancers.
using hormonal or vaginal medications in last 6 months
using other vaginal products or hormonal tablets
infections or vulvovginal lesions such as psoriasis , lichen planus , lichen sclerosis
abnormal pap smear results

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vulvovaginal dryness. Timepoint: Before intervention and after 8 weeks of using according to the given prescription. Method of measurement: Subjective description by 0-4 ( 0: none , 1: mild , 2: moderate, 3: severe , 4 : very severe ).;Vulvovaginal burning. Timepoint: Before intervention and after 8 weeks of using according to the given prescription. Method of measurement: Subjective description by 0-4 ( 0: none , 1: mild , 2: moderate, 3: severe , 4 : very severe ).;Vulvovaginal itching. Timepoint: Before intervention and after 8 weeks of using according to the given prescription. Method of measurement: Subjective description by 0-4 ( 0: none , 1: mild , 2: moderate, 3: severe , 4 : very severe ).;Dyspareunia. Timepoint: Before intervention and after 8 weeks of using according to the given prescription. Method of measurement: Subjective description by 0-4 ( 0: none , 1: mild , 2: moderate, 3: severe , 4 : very severe ).

Secondary Outcome Measures